20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR- and c-Src-dependent mechanism

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 3, 2009, Pages

  Akbulut, Talha ^a   Regner, Kevin R ^a   Roman, Richard J ^a   Avner, Ellis D ^a   Falck, John R ^b   Park, Frank ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cell signaling; Epidermal growth factor receptor; Epithelial cell proliferation

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID DERIVATIVE; BISINDOLYLMALEIMIDE; BOSUTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PELITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C; RAF PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL COMMUNICATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; KIDNEY CELL; KIDNEY EPITHELIUM; MALE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

EID: 69449101237     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00146.2009     Document Type: Article

References (50)

1. Alonso-Galicia M, Falck JR, Reddy KM, Roman RJ. 20-HETE agonists and antagonists in the renal circulation. Am J Physiol Renal Physiol 277: F790-F796, 1999.
2. Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, Miller K, Powell DW, Yaczko D, Young M, Tischler M, Arndt K, Discafani C, Etienne C, Gibbons J, Grod J, Lucas J, Weber JM, Boschelli F. Optimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44: 3965-3977, 2001. (Pubitemid 33051486)
3. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol 71: 159-171, 1976.
4. Chen P, Guo M, Wygle D, Edwards PA, Falck JR, Roman RJ, Scicli AG. Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 166: 615-624, 2005. (Pubitemid 40189056)
5. Chen Y, Medhora M, Falck JR, Pritchard KA Jr, Jacobs ER. Mechanisms of activation of eNOS by 20-HETE and VEGF in bovine pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 291: L378-L385, 2006. (Pubitemid 44343713)
6. Escalante B, Erlij D, Falck JR, McGiff JC. Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science 251: 799-802, 1991. (Pubitemid 21926174)
7. 3 - absorption via a cytochrome P-450-dependent pathway in MTAL. Am J Physiol Renal Physiol 276: F726-F736, 1999.
8. Guo AM, Sheng J, Scicli GM, Arbab AS, Lehman NL, Edwards PA, Falck JR, Roman RJ, Scicli AG. Expression of CYP4A1 in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. J Pharmacol Exp Ther 327: 10-19, 2008.
9. Guo M, Roman RJ, Falck JR, Edwards PA, Scicli AG. Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N′-(4-butyl-2- methylphenyl)formamidine], a selective inhibitor of CYP4A. J Pharmacol Exp Ther 315: 526-533, 2005. (Pubitemid 41500716)
10. Guo M, Roman RJ, Fenstermacher JD, Brown SL, Falck JR, Arbab AS, Edwards PA, Scicli AG. 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N′-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. J Pharmacol Exp Ther 317: 97-108, 2006.
11. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 204: 334-341, 2009.
12. Imig JD, Falck JR, Inscho EW. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol 127: 1399-1405, 1999.
13. Imig JD, Zou AP, Ortiz de Montellano PR, Sui Z, Roman RJ. Cytochrome P-450 inhibitors alter afferent arteriolar responses to elevations in pressure. Am J Physiol Heart Circ Physiol 266: H1879-H1885, 1994. (Pubitemid 24172127)
14. Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol Regul Integr Comp Physiol 270: R217-R227, 1996. (Pubitemid 26062551)
15. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53, 2003. (Pubitemid 36331965)
16. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR. Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature 364: 249-252, 1993. (Pubitemid 23257085)
17. Lange A, Gebremedhin D, Narayanan J, Harder D. 20-Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem 272: 27345-27352, 1997.
18. 2. Am J Physiol Heart Circ Physiol 288: H2306-H2316, 2005.
19. Lin F, Rios A, Falck JR, Belosludtsev Y, Schwartzman ML. 20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol Renal Fluid Electrolyte Physiol 269: F806-F816, 1995. (Pubitemid 3020683)
20. Lombardo CR, Consler TG, Kassel DB. In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c-Src: identification of phosphorylation sites and c-Src SH2 domain binding sites. Biochemistry 34: 16456-16466, 1995.
21. Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 92: 6981-6985, 1995.
22. Maier KG, Roman RJ. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 10: 81-87, 2001. (Pubitemid 32102227)
23. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. In press.
24. Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Uddin MR, Malik KU. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin- dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA 95: 12701-12706, 1998. (Pubitemid 28483828)
25. Muthalif MM, Uddin MR, Fatima S, Parmentier JH, Khandekar Z, Malik KU. Small GTP binding protein Ras contributes to norepinephrine-induced mitogenesis of vascular smooth muscle cells. Prostaglandins Other Lipid Mediat 65: 33-43, 2001. (Pubitemid 32378801)
26. Nilakantan V, Maenpaa C, Jia G, Roman RJ, Park F. 20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells. Am J Physiol Renal Physiol 294: F562-F570, 2008.
27. Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 3: 21-27, 2004. (Pubitemid 39193675)
28. Okutani T, Okabayashi Y, Kido Y, Sugimoto Y, Sakaguchi K, Matuoka K, Takenawa T, Kasuga M. Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. J Biol Chem 269: 31310-31314, 1994. (Pubitemid 24377633)
29. Park F, Sweeney WE, Jia G, Roman RJ, Avner ED. 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease. J Am Soc Nephrol 19: 1929-1939, 2008.
30. Park F, Sweeney WE Jr, Jia G, Akbulut T, Mueller B, Falck JR, Birudaraju S, Roman RJ, Avner ED. Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD. Am J Physiol Renal Physiol 296: F575-F582, 2009.
31. Quigley R, Baum M, Reddy KM, Griener JC, Falck JR. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol Renal Physiol 278: F949-F953, 2000. (Pubitemid 30441360)
32. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol 40: 2707-2719, 2008.
33. Regner KR, Zuk A, Van Why SK, Shames BD, Ryan RP, Falck JR, Manthati VL, McMullen ME, Ledbetter SR, Roman RJ. Protective effect of 20-HETE analogues in experimental renal ischemia-reperfusion injury. Kidney Int 75: 511-517, 2009.
34. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007. (Pubitemid 46763022)
35. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002.
36. Roskoski R Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 331: 1-14, 2005. (Pubitemid 40545134)
37. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol 213: 589-602, 2007. (Pubitemid 350058250)
38. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103: 211-225, 2000.
39. +)ATPase. Nature 314: 620-622, 1985.
40. Sun CW, Falck JR, Harder DR, Roman RJ. Role of tyrosine kinase and PKC in the vasoconstrictor response to 20-HETE in renal arterioles. Hypertension 33: 414-418, 1999.
41. Sweeney WE Jr, Avner ED. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res 326: 671-685, 2006. (Pubitemid 44786367)
42. SweeneyWEJr, von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 19: 1331-1341, 2008.
43. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028, 2000.
44. Tunctan B, Korkmaz B, Buharalioglu CK, Firat SS, Anjaiah S, Falck J, Roman RJ, Malik KU. A 20-hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. Shock 30: 329-335, 2008.
45. Uddin MR, Muthalif MM, Karzoun NA, Benter IF, Malik KU. Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling. Hypertension 31: 242-247, 1998. (Pubitemid 28124723)
46. + channel in the thick ascending limb of the rat kidney. J Gen Physiol 106: 727-743, 1995.
47. Wong KK. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat Anticancer Drug Discov 4: 28-35, 2009.
48. 2, PAF, and LPA1 receptors. Can J Physiol Pharmacol 84: 377-391, 2006.
49. Zou AP, Imig JD, Kaldunski M, Ortiz de Montellano PR, Sui Z, Roman RJ. Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood flow. Am J Physiol Renal Fluid Electrolyte Physiol 266: F275-F282, 1994. (Pubitemid 24104758)
50. Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, Roman RJ. Effect of P-450 ω-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol Renal Fluid Electrolyte Physiol 266: F934-F941, 1994. (Pubitemid 24214643)